Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology

Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology
复制标题

DOI:
10.1002/mrm.10446
复制
发表时间:
2003-05-01
影响因子:
3.3
通讯作者:
Turnbull, DH
Turnbull, DH
中科院分区:
医学3区
文献类型:
--
作者:
Cha, S;Johnson, G;Turnbull, DH

文献摘要

被引文献

相似文献

本研究的目的是开发一种MRI方案,以评估在7 T显微成像系统上植入的GL 261小鼠胶质瘤的生长和血管分布。在肿瘤发展的不同阶段,对34只小鼠进行了常规T-1和T-2加权成像以及动态对比增强T-2(*)加权成像。MRI测量的相对脑血容量(rCBV)进行了比较,微血管密度(MVD)的组织学评估。对比增强后T1加权像的增强与伊文思蓝外渗的组织学评估进行比较。传统的T2加权和增强后的T1加权图像显示肿瘤生长特征与以前描述的GL 261胶质瘤一致。此外,从MRI数据的rCBV的测量与MVD的组织学测量相同的肿瘤是在良好的协议。在GL 261胶质瘤进展的所有阶段,甚至在血管生成证据之前,都观察到T-1加权图像上的对比增强,这表明MRI中常规对比增强的机制不需要新血管生成。这些结果为目前用于评估人类脑肿瘤的MRI方法提供了定量支持,并为基因工程小鼠脑肿瘤模型中血管生成的未来研究奠定了基础。(C)2003 Wiley-Liss,Inc.
The aim of this study was to develop an MRI protocol to evaluate the growth and vascularity of implanted GL261 mouse gliomas on a 7T microimaging system. Both conventional T-1-and T-2-weighted imaging and dynamic, contrast-enhanced T-2(*)-weighted imaging were performed on 34 mice at different stages of tumor development. MRI measurements of relative cerebral blood volume (rCBV) were compared to histological assessments of microvascular density (MVD). Enhancement on postcontrast T-1-weighted images was compared to histological assessments of Evan's blue extravasation. Conventional T2-weighted and postcontrast T-1-weighted images demonstrated tumor growth characteristics consistent with previous descriptions of GL261 glioma. Furthermore, measurements of rCBV from MRI data were in good agreement with histological measurements of MVD from the same tumors. Postcontrast enhancement on T-1-weighted images was observed at all stages of GL261 glioma progression, even before evidence of angiogenesis, indicating that the mechanism of conventional contrast enhancement in MRI does not require neovascularization. These results provide quantitative support for MRI approaches currently used to assess human brain tumors, and form the basis for future studies of angiogenesis in genetically engineered mouse brain tumor models. (C) 2003 Wiley-Liss, Inc.